# Metis Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/metis-technologies

- Industry: Healthcare
- Headquarters: Beijing, China
- Website: www.metispharma.com
- Total disclosed funding: $5.6M
- Latest round: Series D (Aug 4, 2025)
- Investors on record: 2

## About

Metis Technologies, based in Beijing, China, is a biotechnology company focused on developing innovative AI-driven nano-materials for advanced drug delivery systems. Their solutions aim to enhance precision in therapeutic applications.Founded in 2020, Metis Technologies specializes in the biopharmaceutical sector, offering AI-enhanced solutions for targeted drug delivery. The company has raised CNY 40 million in Series D funding, co-led by Beijing Medical and Health and Beishang Capital, with their latest deal occurring on August 4, 2025.Metis Technologies specializes in innovative AI-driven nano-materials designed for targeted delivery systems. Their core product, the AiLNP platform, leverages artificial intelligence to optimize lipid nanoparticle (LNP) delivery systems, primarily utilized in biopharmaceutical applications, including oncology and regenerative medicine. The company serves global markets across North America, Europe, and Asia, partnering with research institutions and pharmaceutical companies.The revenue model for Metis Technologies is centered around collaborations with biopharmaceutical companies and research entities, focusing on research and development funding or milestone payments. Their flagship AiLNP platform plays a significant role in these transactions, which may include licensing fees or service charges linked to AI integration and support.In August 2025, Metis Technologies secured CNY 40 million in Series D funding, which will accelerate automation upgrades, advance their product pipeline, strengthen international partnerships, and attract high-end talent. The company plans to launch new products targeting specific therapeutic areas and expand its market presence into additional regions by the end of 2026.

## Funding rounds

- Series D, Aug 4, 2025, $5.6M — Shunxi Fund, Beishang Capital

## Investors

- Shunxi Fund (https://capitalatlas.ai/funds/shunxi-fund) — Series D
- Beishang Capital (https://capitalatlas.ai/funds/beishang-capital) — Series D